Stockreport

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics, Inc.  (TNGX) 
PDF – Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months–  – Combination studies with RAS(ON) in [Read more]